Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

FDA sees no heart risks from Novartis’ Parkinson’s drug

Written by: | no-reply@reuters.com | Dated: Monday, October 26th, 2015

U.S. health regulators said on Monday that there was no evidence of increased cardiovascular risks related to Novartis AG’s treatment, Stalevo, for Parkinson’s disease.

Recommendations for using the drug, which won U.S. approval in 2003, will remain the same on the labels, the U.S. Food and Drug Administration said, after examining data from a required clinical trial and one additional study. (1.usa.gov/1R9cqP6)

The agency had warned patients and healthcare professionals about such risks in August 2010, after it identified certain issues in a clinical trial comparing Stalevo with a combination of drugs, carbidopa and levodopa.

The combination treatment has not shown any increased cardiovascular risks.

U.S-listed shares of the Swiss drugmaker were little changed at $92.33 on the New York Stock Exchange on Monday.

 

 

(Reporting By Samantha Kareen Nair in Bengaluru; Editing by Anil D’Silva)

Source: Reuters Health

http://www.reuters.com/article/2015/10/26/us-novartis-fda-idUSKCN0SK24U20151026

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom